Share /
Feb 7, 2021 at 10:04 AM
Promoted
In order to gain insight into how organizations are thinking about digitizing medical documents and the strategy behind those decisions, we’re conducting a brief survey of the MedCity News audience and will publish a report based on this survey’s findings.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
MedCity News
Bristol Myers lymphoma therapy acquired in Celgene deal wins FDA nod
After some setbacks and delays, the FDA approved Bristol Myers Squibb’s Breyanzi for certain lymphomas. It’s the fourth CAR T treatment to win the regulatory nod and the first under a new regenerative medicine designation.
Shares1
A Bristol Myers Squibb cancer immunotherapy that the pharmaceutical giant obtained via its Celgene acquisition was awarded FDA approval Friday, adding one more of this type of personalized medicine as a treatment option for certain forms of lymphoma.
The FDA approved the therapy, lisocabtagene maraleucel, as a treatment for adults who have certain types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL), whose cancer has not responded to or has relapsed after at least two other types of treatment. New York-based BMS will market the drug under the name Breyanzi.
Astrata, a spinout of UPMC's innovation arm, has developed natural language processing tools that can help providers and payers adhere to quality measures. This can, in turn, help healthcare organizations bolster their finances as reimbursement is increasingly being tied to these measures.
In adding more conditions, is Onduo becoming a me-too platform of Omada and Livongo?
Verily’s virtual diabetes platform, Onduo, is expanding to support additional conditions and languages, Onduo’s CEO Vindell Washington shared. How will the company differentiate itself among a growing number of multi-condition platforms, such as Livongo and Omada?
Shares1
Verily’s Onduo, a digital health platform for managing type 2 diabetes, is expanding to offer tools for hypertension and mental wellness. Photo credit: Verily
Following in the footsteps of its digital health competitors, Livongo and Omada Health, Onduo recently added programs for hypertension and mental wellness to its diabetes platform.